GlassScriptPhysician profile
Olusola Akenroye
NPI 1902247968
$4,306.50
in general payments reported to CMS, 2019-2025
12 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $1,627 · 2023: $904 · 2024: $612 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Travel and Lodging: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.70 |
| Travel and Lodging | $374.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,824.45 | 2021-2024 | Vanta Adaptivestim, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $560.33 | 2021-2025 | Intracept |
| Abbvie INC. | $201.10 | 2021-2022 | |
| Spr Therapeutics, INC | $196.51 | 2024 | Sprint Pns System |
| Abbott Laboratories | $155.67 | 2021-2022 | |
| Allergan, INC. | $99.65 | 2021-2022 | |
| Relievant Medsystems, INC. | $68.59 | 2021 | |
| Painteq LLC | $57.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $42.53 | 2021 | |
| Nevro Corp. | $39.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.21 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusola Akenroye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.